Celebrating 60 years of melanoma research to save lives
19 April 2017
Melanoma Institute Australia is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
It was back in 1957 when Sydney Hospital recorded its first data on a melanoma patient. This patient record marked the beginning of what was to become the Melanoma Research Database (MRD), which is now the biggest database of its kind in the world. With more than 41,000 patient records, the MRD continues to play a vital role in underpinning the ground-breaking work of Melanoma Institute Australia (MIA) and around the world.
“Melanoma used to be viewed as a disease with a dismal outlook for patients, but I am pleased to say that today things are much different,” said Professor Richard Scolyer, MIA’s Conjoint Medical Director. “The foresight of our colleagues at Sydney Hospital to start recording patient data back in 1957 set us on a path towards greater understanding of the disease, and we are now leading the world in advancing melanoma treatment and research.”
“Life expectancy for advanced melanoma patients has tripled in the last five years, and we are even seeing some patients who are recovering fully,” comments Professor Georgina Long, MIA’s Conjoint Medical Director. “However we still have a long way to go, with one Australian dying from melanoma every six hours.”
Critical to our story is the work of Professor Gerry Milton (pictured) of the Sydney Melanoma Unit (now Melanoma Institute Australia) who in 1968 was trying to better understand the disease. He recruited Dr Helen Shaw to collect and collate all the records of melanoma patients treated at Sydney Hospital over the previous decade. Always forward thinking, the Unit decided to embrace the “high technology” of the day and convert the entire patient catalogue to punch cards – and so the database was born. The detailed patient records included diagnosis, treatment and disease course over time.
The MRD database is now managed by a team including IT specialists and clinical data managers, dedicated to its refinement, preservation and cultivation. It serves as an invaluable resource to identify and extract specific sub-sets of information for research projects related to causes, diagnosis, prognosis and treatment outcomes in melanoma patients. The knowledge gained from these studies assists in the management of melanoma patients around the world.
“We celebrate this Diamond Anniversary with much gratitude to our professional predecessors for their pioneering work that was way ahead of its time. We also have immense appreciation for those thousands of melanoma patients who over the last 60 years have allowed their clinical records to be included in our research database which have enabled us to improve the lives of melanoma patients that have followed them,” Professor Scolyer said.
“They have quite literally given the gift of life to other melanoma patients, and will be the unsung heroes when we finally achieve our goal of ending melanoma.”
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.